Core Insights - Samsung Epis Holdings has established a new subsidiary, Epis NexLab, to focus on the development of next-generation biotechnology platforms [2][7][9] - The new subsidiary aims to leverage R&D expertise from biosimilar development to create scalable technologies for discovering new drug candidates [2][4][5] - Peter Seongwon Hong will serve as CEO of Epis NexLab while continuing his role at Samsung Bioepis [3][4] Company Strategy - Epis NexLab will transform peptide-related technologies into platforms for innovative treatment modalities targeting various diseases [5][4] - The company plans to explore new modalities, including amino acid or peptide conjugate platform technologies, to drive sustainable growth beyond the biosimilar business [2][4] - The long-term goal is to become a leading biotechnology company in next-generation therapeutic technologies through innovative R&D and strategic investments [4][5]

INCHEON, Korea--(BUSINESS WIRE)-- #BYOOVIZ--Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis' two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen b. ...